Canada · Delayed Price · Currency is CAD Apotex Health Statistics
Total Valuation
Apotex Health has a market cap or net worth of CAD 9.06 billion. The enterprise value is 12.53 billion.
| Market Cap | 9.06B |
| Enterprise Value | 12.53B |
Important Dates
The next confirmed earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Apotex Health has 228.50 million shares outstanding.
| Current Share Class | 228.50M |
| Shares Outstanding | 228.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | n/a |
| Float | 228.18M |
Valuation Ratios
The trailing PE ratio is 20.74 and the forward PE ratio is 19.70. Apotex Health's PEG ratio is 1.01.
| PE Ratio | 20.74 |
| Forward PE | 19.70 |
| PS Ratio | 2.60 |
| PB Ratio | -16.25 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 17.44 |
| P/OCF Ratio | 14.14 |
| PEG Ratio | 1.01 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.27, with an EV/FCF ratio of 24.10.
| EV / Earnings | 33.52 |
| EV / Sales | 3.59 |
| EV / EBITDA | 10.27 |
| EV / EBIT | 11.71 |
| EV / FCF | 24.10 |
Financial Position
The company has a current ratio of 1.50
| Current Ratio | 1.50 |
| Quick Ratio | 0.77 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.89 |
| Debt / FCF | 6.77 |
| Interest Coverage | 4.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 14.23% |
| Return on Invested Capital (ROIC) | 25.83% |
| Return on Capital Employed (ROCE) | 34.57% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 561,588 |
| Profits Per Employee | 60,131 |
| Employee Count | 6,216 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 1.63 |
Taxes
In the past 12 months, Apotex Health has paid 146.09 million in taxes.
| Income Tax | 146.09M |
| Effective Tax Rate | 28.10% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 76.05 |
| Average Volume (20 Days) | 331,222 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Apotex Health had revenue of CAD 3.49 billion and earned 373.78 million in profits. Earnings per share was 1.91.
| Revenue | 3.49B |
| Gross Profit | 1.94B |
| Operating Income | 1.07B |
| Pretax Income | 519.87M |
| Net Income | 373.78M |
| EBITDA | 1.19B |
| EBIT | 1.07B |
| Earnings Per Share (EPS) | 1.91 |
Balance Sheet
The company has 56.99 million in cash and 3.52 billion in debt, with a net cash position of -3.46 billion or -15.16 per share.
| Cash & Cash Equivalents | 56.99M |
| Total Debt | 3.52B |
| Net Cash | -3.46B |
| Net Cash Per Share | -15.16 |
| Equity (Book Value) | -557.93M |
| Book Value Per Share | -2.89 |
| Working Capital | 724.68M |
Cash Flow
In the last 12 months, operating cash flow was 640.96 million and capital expenditures -121.06 million, giving a free cash flow of 519.90 million.
| Operating Cash Flow | 640.96M |
| Capital Expenditures | -121.06M |
| Depreciation & Amortization | 119.04M |
| Net Borrowing | 829.98M |
| Free Cash Flow | 519.90M |
| FCF Per Share | 2.28 |
Margins
Gross margin is 55.65%, with operating and profit margins of 30.65% and 10.71%.
| Gross Margin | 55.65% |
| Operating Margin | 30.65% |
| Pretax Margin | 14.89% |
| Profit Margin | 10.71% |
| EBITDA Margin | 34.06% |
| EBIT Margin | 30.65% |
| FCF Margin | 14.89% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 0.53%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 0.53% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 296.87% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.53% |
| Earnings Yield | 4.12% |
| FCF Yield | 5.74% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Apotex Health is 40.69, which is 2.57% higher than the current price. The consensus rating is "Buy".
| Price Target | 40.69 |
| Price Target Difference | 2.57% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 5.33% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Apotex Health has an Altman Z-Score of 1.44 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.44 |
| Piotroski F-Score | 4 |